Point of Care Molecular Diagnostics Market Size, Trends 2031

Segments - Point-of-Care Molecular Diagnostics Market by Test Locations (OTC and PoC), Applications (Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology and Others), End-users (Decentralized Labs, Hospitals, Homecare, Assisted Living Healthcare Facilities, and Others), Technology (PCR-based, Genetic Sequencing-based, Hybridization-based, and Microarray-based), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021–2028

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

The global point-of-care molecular diagnostics market size is projected to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing demand for faster and accurate testing methods.

Global Point Of Care Molecular Diagnostics Market Outlook

Point-of-care (PoC) molecular diagnostics allows and enables physicians to enhance the standard of healthcare of patients by providing quick diagnosis with arriving at effective treatment decision in the first visit. This testing method helps doctors to prescribe an accurate treatment for patients in the first instance without waiting for the final results since it can detect the infections and also determine a patient’s ability to metabolize a drug or drug class. The testing also can detect minimal residual disease besides offering faster analysis of the diagnostics result with lowering the price per test.

These developments are made possible due to rapid introduction of modern innovative techniques and production of advanced diagnostic devices. The use of mutation-specific targeted analysis for diagnosing of the ‘single gene’ ailments and parallel next-gene sequencing are providing key opportunities for rising demand for PoC molecular diagnostics.

In the recent times, several players of the healthcare industry are extensively focusing on the development of two key aspects of molecular diagnosis such as prevention and early detection rather than finding a cure. As a result of these development, it is observed that the revenue flow is progressively visible to areas widely associated with PoC testing enhancement and diagnostic capabilities. In the coming years, rise in number of new product development and product commercialization are projected to boost the PoC molecular diagnostics market growth.

Market Drivers, Restraints, Trends, and Opportunities

Growing adoption and miniaturization of current technology along with increasing demand for faster and accurate testing methods are expected to boost the demand for molecular diagnostics.
Rising funding from government organizations and other private firms encouraging research and development activities to develop innovative and effective testing kits are projected to propel the market expansion.
Growing awareness of the benefits associated with molecular mechanisms in the detection of common and rare disorders are key factors driving the market.
Rapid growth of a number of clinical studies investigating the efficiency and accuracy of novel molecular tests are expected to spur market growth during the forecast period.
Ongoing R&D activities, product commercialization, market adoption, penetration rates, POC MDx application & usage are key aspects that can create several opportunities for the market expansion.
The outbreak of COVID-19 pandemic has positively impacted the market growth. Increasing demand for PCR and RT-PCR kits during the COVID-19 pandemic has increased the adoption of the point of care molecular diagnostics.

Scope of Point-of-Care Molecular Diagnostics Market Report

The report on the global point-of-care molecular diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Point-of-Care Molecular Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2020
Historic Data	2018–2019
Forecast Period	2021–2028
Segmentation	Test Locations (OTC and PoC), Applications (Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology, and others), End-users (Decentralized Labs, Hospitals, Homecare, Assisted Living Healthcare Facilities, and Others), and Technology (PCR-based, Genetic Sequencing-based, Hybridization-based, and Microarray-based)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	Abbott Laboratories; Bayer Healthcare; F. Hoffmann-La Roche AG; Becton, Dickinson and Company; BioMerieux; Bio-Rad Laboratories, Inc.; Cepheid, Inc.; Danaher Corporation; and Johnson and Johnson.

Global Point-of-Care Molecular Diagnostics Market Segment Insights

OTC tests segment is anticipated to represent a considerable market share

On the basis of test locations, the point-of-care molecular diagnostics market is bifurcated into PoC and over-the-counter (OTC) tests. The OTC tests segment is anticipated to represent a considerable market share during the forecast period due to high flexibility and portability of the OTC tests as compared to PoC tests, in terms of assisted living facilities and usage at home.

OTC users generally constitute non-skilled personnel and in most of the cases, the patients personally use the test themselves. Additionally, a large number of these test devices are CLIA waived, encouraging the users to use these tests in non-laboratory settings. Moreover, OTC tests are ease to use, greater adoption rate, and easy availability, which present key factors for the segment growth.

Global Point Of Care Molecular Diagnostics Test Locations

Infectious diseases segment projected to constitute a significant market share

In terms of applications, the market is classified as infectious diseases, oncology, hematology, prenatal testing, endocrinology, and others. The infectious diseases segment is projected to constitute a significant market share during the forecast period. Rising prevalence of infectious diseases and growing demand for oncology PoC molecular tests represent major drivers for the segment growth. The diagnostics provide crucial information and data about suitable antimicrobial treatment, efficient disease management, enhanced distribution of healthcare laboratory assets, and reduced mortality and costs in relation to the treatment of infectious diseases.

Decentralized laboratories segment expected to account for a key market share

On the basis of end-users, the point-of-care molecular diagnostics market is divided into decentralized laboratories, hospitals, homecare, assisted living healthcare facilities, and others. The decentralized laboratories segment is expected to account for a key market share during the forecast period. The decentralized laboratories tests are capable of providing rapid and accurate molecular analysis, while having a smaller footprint as compared to the central laboratory-based counterparts. These factors are contributing to the growth of decentralized laboratories segment.

Global Point Of Care Molecular Diagnostics End Users

PCR-based test segment estimated to represent a significant market share

Based on technology, the market is divided into PCR-based, genetic sequencing-based, hybridization-based, and microarray-based tests. The PCR-based test segment is estimated to represent a significant market share during the forecast period. Commercialization of PoC tests that offer rapid real time PCR analysis, having high level of accuracy for infectious diseases such as H1N1 and influenza are projected to drive the segment growth.

On the other hand, the genetic sequencing-based segment is expected to exhibit a high CAGR during the forecast period owing to rapid technological changes in the platforms enabling genetic sequencing and analysis of DNA data at the point of care with improved accuracy. Rapid DNA analysis is anticipated to witness a considerable growth during the forecast period owing to the continuous innovation and R&D by key market players.

Asia Pacific projected to register a robust CAGR

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in Asia Pacific is projected to register a robust CAGR during the forecast period owing to rising awareness of molecular diagnostics to detect the diseases infection at early stage. The lack of sophisticated central laboratory testing services, cost-effective implementation of PoC molecular, and a large population base in need for clinical testing tests are the key factors driving the regional growth of the market.

The market in Europe, on the other hand, is estimated to expand at a high CAGR during the forecast period owing to the increasing demand for rapid diagnosis and development of newer molecular diagnostic tests for DNA analysis.

Segments

The global point-of-care molecular diagnostic market has been segmented on the basis of

Test Locations

Applications

Infectious Diseases
Oncology
Hematology
Prenatal Testing
Endocrinology
Others

End-users

Decentralized Labs
Hospitals
Homecare
Assisted Living Healthcare Facilities
Others

Technology

PCR-based
Genetic Sequencing-based
Hybridization-based
Microarray-based

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

Abbott Laboratories
Bayer Healthcare
F. Hoffmann-La Roche AG
Becton, Dickinson and Company
BioMerieux
Bio-Rad Laboratories, Inc.
Cepheid, Inc.
Danaher Corporation
Johnson and Johnson.

Competitive Landscape

Some of the key players in the global point-of-care molecular diagnostics market include Abbott Laboratories; Bayer Healthcare; F. Hoffmann-La Roche AG; Becton, Dickinson and Company; BioMerieux; Bio-Rad Laboratories, Inc.; Cepheid, Inc.; Danaher Corporation; and Johnson and Johnson.

The market is shifting towards a phase of consolidation, amalgamation, and acquisitions owing to the development and commercialization of novel miniaturized molecular diagnostic tests by key players. Additionally, these players are increasingly focusing on strengthening their market positions using several market strategies such as product launches, entering into partnerships, and expansion of the production units.

Global Point Of Care Molecular Diagnostics Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Point-of-Care Molecular Diagnostics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Point-of-Care Molecular Diagnostics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Point-of-Care Molecular Diagnostics Market - Supply Chain
  4.5. Global Point-of-Care Molecular Diagnostics Market Forecast
     4.5.1. Point-of-Care Molecular Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Point-of-Care Molecular Diagnostics Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Point-of-Care Molecular Diagnostics Market Absolute $ Opportunity
5. Global Point-of-Care Molecular Diagnostics Market Analysis and Forecast by Applications
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Applications
     5.2.2. Y-o-Y Growth Projections by Applications
  5.3. Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by Applications
     5.3.1. Infectious Diseases
     5.3.2. Oncology
     5.3.3. Hematology
     5.3.4. Prenatal Testing
     5.3.5. Endocrinology
     5.3.6. Others
  5.4. Absolute $ Opportunity Assessment by Applications
  5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Point-of-Care Molecular Diagnostics Market Analysis and Forecast by End Users
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by End Users
     6.2.2. Y-o-Y Growth Projections by End Users
  6.3. Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by End Users
     6.3.1. Decentralized Labs
     6.3.2. Hospitals
     6.3.3. Homecare
     6.3.4. Assisted Living Healthcare Facilities
     6.3.5. Others
  6.4. Absolute $ Opportunity Assessment by End Users
  6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Point-of-Care Molecular Diagnostics Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Point-of-Care Molecular Diagnostics Demand Share Forecast, 2019-2026
8. North America Point-of-Care Molecular Diagnostics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by Applications
     8.4.1. Infectious Diseases
     8.4.2. Oncology
     8.4.3. Hematology
     8.4.4. Prenatal Testing
     8.4.5. Endocrinology
     8.4.6. Others
  8.5. Basis Point Share (BPS) Analysis by Applications
  8.6. Y-o-Y Growth Projections by Applications
  8.7. North America Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by End Users
     8.7.1. Decentralized Labs
     8.7.2. Hospitals
     8.7.3. Homecare
     8.7.4. Assisted Living Healthcare Facilities
     8.7.5. Others
  8.8. Basis Point Share (BPS) Analysis by End Users
  8.9. Y-o-Y Growth Projections by End Users
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Point-of-Care Molecular Diagnostics Demand Share Forecast, 2019-2026
9. Latin America Point-of-Care Molecular Diagnostics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by Applications
     9.4.1. Infectious Diseases
     9.4.2. Oncology
     9.4.3. Hematology
     9.4.4. Prenatal Testing
     9.4.5. Endocrinology
     9.4.6. Others
  9.5. Basis Point Share (BPS) Analysis by Applications
  9.6. Y-o-Y Growth Projections by Applications
  9.7. Latin America Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by End Users
     9.7.1. Decentralized Labs
     9.7.2. Hospitals
     9.7.3. Homecare
     9.7.4. Assisted Living Healthcare Facilities
     9.7.5. Others
  9.8. Basis Point Share (BPS) Analysis by End Users
  9.9. Y-o-Y Growth Projections by End Users
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Point-of-Care Molecular Diagnostics Demand Share Forecast, 2019-2026
10. Europe Point-of-Care Molecular Diagnostics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by Applications
     10.4.1. Infectious Diseases
     10.4.2. Oncology
     10.4.3. Hematology
     10.4.4. Prenatal Testing
     10.4.5. Endocrinology
     10.4.6. Others
  10.5. Basis Point Share (BPS) Analysis by Applications
  10.6. Y-o-Y Growth Projections by Applications
  10.7. Europe Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by End Users
     10.7.1. Decentralized Labs
     10.7.2. Hospitals
     10.7.3. Homecare
     10.7.4. Assisted Living Healthcare Facilities
     10.7.5. Others
  10.8. Basis Point Share (BPS) Analysis by End Users
  10.9. Y-o-Y Growth Projections by End Users
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Point-of-Care Molecular Diagnostics Demand Share Forecast, 2019-2026
11. Asia Pacific Point-of-Care Molecular Diagnostics Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by Applications
     11.4.1. Infectious Diseases
     11.4.2. Oncology
     11.4.3. Hematology
     11.4.4. Prenatal Testing
     11.4.5. Endocrinology
     11.4.6. Others
  11.5. Basis Point Share (BPS) Analysis by Applications
  11.6. Y-o-Y Growth Projections by Applications
  11.7. Asia Pacific Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by End Users
     11.7.1. Decentralized Labs
     11.7.2. Hospitals
     11.7.3. Homecare
     11.7.4. Assisted Living Healthcare Facilities
     11.7.5. Others
  11.8. Basis Point Share (BPS) Analysis by End Users
  11.9. Y-o-Y Growth Projections by End Users
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Point-of-Care Molecular Diagnostics Demand Share Forecast, 2019-2026
12. Middle East & Africa Point-of-Care Molecular Diagnostics Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by Applications
     12.4.1. Infectious Diseases
     12.4.2. Oncology
     12.4.3. Hematology
     12.4.4. Prenatal Testing
     12.4.5. Endocrinology
     12.4.6. Others
  12.5. Basis Point Share (BPS) Analysis by Applications
  12.6. Y-o-Y Growth Projections by Applications
  12.7. Middle East & Africa Point-of-Care Molecular Diagnostics Market Size and Volume Forecast by End Users
     12.7.1. Decentralized Labs
     12.7.2. Hospitals
     12.7.3. Homecare
     12.7.4. Assisted Living Healthcare Facilities
     12.7.5. Others
  12.8. Basis Point Share (BPS) Analysis by End Users
  12.9. Y-o-Y Growth Projections by End Users
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Point-of-Care Molecular Diagnostics Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Point-of-Care Molecular Diagnostics Market: Market Share Analysis
  13.2. Point-of-Care Molecular Diagnostics Distributors and Customers
  13.3. Point-of-Care Molecular Diagnostics Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Abbott Laboratories
     13.4.2. Bayer Healthcare
     13.4.3. F. Hoffmann-La Roche AG
     13.4.4. Becton, Dickinson and Company
     13.4.5. BioMerieux
     13.4.6. Bio-Rad Laboratories, Inc.
     13.4.7. Cepheid, Inc.
     13.4.8. Danaher Corporation
     13.4.9. Johnson and Johnson.